Literature DB >> 26161356

MEF2C-Related 5q14.3 Microdeletion Syndrome Detected by Array CGH: A Case Report.

Jae Sun Shim1, Kyunghoon Min1, Seung Hoon Lee1, Ji Eun Park2, Sang Hee Park2, MinYoung Kim1, Sung Han Shim3.   

Abstract

Genetic screening is being widely applied to trace the origin of global developmental delay or intellectual disability. The 5q14.3 microdeletion has recently been uncovered as a clinical syndrome presenting with severe intellectual disability, limited walking ability, febrile convulsions, absence of speech, and minor brain malformations. MEF2C was suggested as a gene mainly responsible for the 5q14.3 microdeletion syndrome. We present the case of a 6-year-old girl, who is the first patient in Korea with de novo interstitial microdeletions involving 5q14.3, showing the typical clinical features of 5q14.3 microdeletion syndrome with a smaller size of chromosomal involvement compared to the previous reports. The microdeletion was not detected by subtelomeric multiplex ligation-dependent probe amplification, but by array comparative genomic hybridization, which is advisable for the detection of a small-sized genetic abnormality.

Entities:  

Keywords:  5q14.3 deletion; Chromosomal aberrations; Developmental disabilities

Year:  2015        PMID: 26161356      PMCID: PMC4496521          DOI: 10.5535/arm.2015.39.3.482

Source DB:  PubMed          Journal:  Ann Rehabil Med        ISSN: 2234-0645


  11 in total

1.  Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression.

Authors:  Markus Zweier; Anne Gregor; Christiane Zweier; Hartmut Engels; Heinrich Sticht; Eva Wohlleber; Emilia K Bijlsma; Susan E Holder; Martin Zenker; Eva Rossier; Ute Grasshoff; Diana S Johnson; Lisa Robertson; Helen V Firth; Arif B Ekici; André Reis; Anita Rauch
Journal:  Hum Mutat       Date:  2010-06       Impact factor: 4.878

2.  Severe mental retardation, seizures, and hypotonia due to deletions of MEF2C.

Authors:  Beata A Nowakowska; Ewa Obersztyn; Krystyna Szymańska; Monika Bekiesińska-Figatowska; Zhilian Xia; Christian B Ricks; Ewa Bocian; David W Stockton; Krzysztof Szczałuba; Magdalena Nawara; Ankita Patel; Daryl A Scott; Sau Wai Cheung; Timothy P Bohan; Paweł Stankiewicz
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-07       Impact factor: 3.568

Review 3.  Copy number variations and clinical cytogenetic diagnosis of constitutional disorders.

Authors:  Charles Lee; A John Iafrate; Arthur R Brothman
Journal:  Nat Genet       Date:  2007-07       Impact factor: 38.330

Review 4.  Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.

Authors:  David T Miller; Margaret P Adam; Swaroop Aradhya; Leslie G Biesecker; Arthur R Brothman; Nigel P Carter; Deanna M Church; John A Crolla; Evan E Eichler; Charles J Epstein; W Andrew Faucett; Lars Feuk; Jan M Friedman; Ada Hamosh; Laird Jackson; Erin B Kaminsky; Klaas Kok; Ian D Krantz; Robert M Kuhn; Charles Lee; James M Ostell; Carla Rosenberg; Stephen W Scherer; Nancy B Spinner; Dimitri J Stavropoulos; James H Tepperberg; Erik C Thorland; Joris R Vermeesch; Darrel J Waggoner; Michael S Watson; Christa Lese Martin; David H Ledbetter
Journal:  Am J Hum Genet       Date:  2010-05-14       Impact factor: 11.025

5.  [Detection of subtelomeric chromosomal rearrangements in idiopathic mental retardation].

Authors:  Gabriella P Szabó; Beáta Bessenyei; Erzsébet Balogh; Anikó Ujfalusi; Katalin Szakszon; Eva Oláh
Journal:  Orv Hetil       Date:  2010-07-04       Impact factor: 0.540

6.  Outcome of the routine assessment of patients with mental retardation in a genetics clinic.

Authors:  A G Hunter
Journal:  Am J Med Genet       Date:  2000-01-03

7.  De novo 5q14.3 translocation 121.5-kb upstream of MEF2C in a patient with severe intellectual disability and early-onset epileptic encephalopathy.

Authors:  Hirotomo Saitsu; Noboru Igarashi; Mitsuhiro Kato; Ippei Okada; Tomoki Kosho; Osamu Shimokawa; Yuki Sasaki; Kiyomi Nishiyama; Yoshinori Tsurusaki; Hiroshi Doi; Noriko Miyake; Naoki Harada; Kiyoshi Hayasaka; Naomichi Matasumoto
Journal:  Am J Med Genet A       Date:  2011-10-11       Impact factor: 2.802

8.  Refining the phenotype associated with MEF2C haploinsufficiency.

Authors:  F Novara; S Beri; R Giorda; E Ortibus; S Nageshappa; F Darra; B Dalla Bernardina; O Zuffardi; H Van Esch
Journal:  Clin Genet       Date:  2010-11       Impact factor: 4.438

9.  De novo microdeletion of 5q14.3 excluding MEF2C in a patient with infantile spasms, microcephaly, and agenesis of the corpus callosum.

Authors:  Keiko Shimojima; Akihisa Okumura; Harushi Mori; Shinpei Abe; Mitsuru Ikeno; Toshiaki Shimizu; Toshiyuki Yamamoto
Journal:  Am J Med Genet A       Date:  2012-07-27       Impact factor: 2.802

10.  A novel microdeletion syndrome involving 5q14.3-q15: clinical and molecular cytogenetic characterization of three patients.

Authors:  Hartmut Engels; Eva Wohlleber; Alexander Zink; Juliane Hoyer; Kerstin U Ludwig; Felix F Brockschmidt; Dagmar Wieczorek; Ute Moog; Birgit Hellmann-Mersch; Ruthild G Weber; Lionel Willatt; Martina Kreiss-Nachtsheim; Helen V Firth; Anita Rauch
Journal:  Eur J Hum Genet       Date:  2009-05-27       Impact factor: 4.246

View more
  1 in total

Review 1.  Progress on the roles of MEF2C in neuropsychiatric diseases.

Authors:  Zhikun Zhang; Yongxiang Zhao
Journal:  Mol Brain       Date:  2022-01-06       Impact factor: 4.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.